Phase 1 N=20 Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection
Type2 Diabetes Mellitus
Primary: Cmax (Maximum Observed Plasma Concentration) — 95.9; 121.6 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=132 Mindful Stress Reduction in Diabetes Self-management Education for Veterans
Diabetes Mellitus
Primary: Problem Areas in Diabetes Scale (PAID) -(Measures Diabetes Distress) — 27.58; 31.24; 17.00; 20.83 units on a scale — p=0.153
Phase 2 N=33 Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
Cervical Cancer · Endometrial Cancer
Primary: Proportion of Patients Who Are Progression-free at 6 Months — 0.29 Proportion of patients
N/A N=10 Intraoperative Investigation of a Directional Lead and Local Field Potentials for the Optimization of Stimulation Efficacy
Parkinson
Primary: Number of DBS Leads With Clinical Programming at 3 Months That Were Consistent With Predictions Via LFP Features After DBS Implant Procedure — 2; 3; 0; 2 DBS leads
N/A N=590 Evaluation Study of the Online High School Media Aware Program
Sexual Behavior
Primary: Willingness to Have Sex — 2.22; 2.30 units on a scale — p=0.41
N/A N=22 Remote Microphone Candidacy Study
Hearing Loss, Sensorineural
Primary: Change in Abbreviated Profile of Hearing Aid Benefit (APHAB) — 7.64; 12.5; 4.8; 6.3 % of Problems (Change from baseline)
Phase 4 N=1,251 UW Quitting Using Intensive Treatment Study (QUITS)
Tobacco Dependence
Primary: 52-Week Point-Prevalence Abstinence — 74; 79; 78; 76 Participants — p=.66
Phase 2 N=180 Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Primary: Overall Survival — 8.8; 9.8 months — p=0.72
N/A N=301 Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)
Rosacea
Primary: Satisfaction Among Patients to Whom Mirvaso®/OnrelteaTM is Prescribed Question — 55; 86; 38; 31 Participants
N/A N=69 Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant
Primary Open Angle Glaucoma
Primary: Number of Eyes With Study Success — 50; 52; 50; 51 Implanted eyes
N/A N=288 Spatz Adjustable Balloon for Obesity (SABO)
Obesity
Primary: Percent Change in Total Body Weight (%TBL) . — 15.0; 3.3 TBL%
Phase 1 N=21 Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)
HIV-1 Infection
Primary: Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) Concentration — -0.82; -1.00; -1.61; -1.81 log10 copies/mL
Phase 3 N=499 Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa
Acute Otitis Externa
Primary: Number of Participants With Clinical Cure of AOE — 190; 191 Participants
N/A N=80 An Adaptive Intervention for Adolescents at Risk for Suicide: A Pilot SMART
Suicide · Self Harm
Primary: Percentage of Eligible Participants Recruited to the Study — 87.2 Percentage of eligible participants
N/A N=107 Post Market Study of the InnFocus MicroShunt
Primary Open Angle Glaucoma
Primary: Number of Participants With Study Success — 62; 59; 58; 60 Participants